EBITDA QualityThere is a negative perception surrounding Healthcare-driven EBITDA beats due to cost releases, which investors might see as lower quality compared to topline-driven growth.
Life Sciences ChallengesThere is a clear lack of visibility on FY25 Life Sciences trends, with Bioprocessing numbers below mid-term expectations.
Sales ExpectationsThe guidance indicates that the upper end of the sales range is out of reach, aligning with previous messaging but possibly disappointing investors hoping for higher sales figures.